Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1150
0.00 (0.00%)
Sep 16, 2026, 12:33 PM AEST
Invex Therapeutics Company Description
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia.
It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial.
The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Contact Details
Address: 101 St Georges Terrace Perth, Washington 6000 Australia | |
| Phone | 61 8 6558 0886 |
| Website | invextherapeutics.com |
Stock Details
| Ticker Symbol | IXC |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000048621 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Ryan Slate | Company Secretary |